BMJ Open

Maternal metabolic profiling to assess fetal gestational age and predict preterm delivery: a two-centre retrospective cohort study in the US

Karl G Sylvester,1 Shiyong Hao,2,3 Jin You,1 Le Zheng,2,3 Lu Tian,4 Xiaoming Yao,5 Lihong Mo,6 Subhashini Ladella,6 Ronald J Wong,7 Gary M Shaw,7 David K Stevenson,7 Harvey J Cohen,7 John C Whitin,7 Doff B McElhinney,2,3 Xuefeng B Ling1,3

ABSTRACT

Objectives The aim of this study was to develop a single blood test that could determine gestational age and estimate the risk of preterm birth by measuring serum metabolites. We hypothesised that serial metabolic modelling of serum analytes throughout pregnancy could be used to describe fetal gestational age and project preterm birth with a high degree of precision.

Study design A retrospective cohort study.

Setting Two medical centres from the USA.

Participants Thirty-six patients (20 full-term, 16 preterm) enrolled at Stanford University were used to develop gestational age and preterm birth risk algorithms; 22 patients (9 full-term, 13 preterm) enrolled at the University of Alabama were used to validate the algorithms.

Outcome measures Maternal blood was collected serially throughout pregnancy. Metabolic datasets were generated using mass spectrometry.

Results A model to determine gestational age was developed ($R^2=0.98$) and validated ($R^2=0.81$). 66.7% of the estimates fell within ±1 week of ultrasound results during model validation. Significant disruptions from full-term pregnancy metabolic patterns were observed in preterm pregnancies ($R^2=-0.68$). A separate algorithm to predict preterm birth was developed using a set of 10 metabolic pathways that resulted in an area under the curve of 0.96 and 0.92, a sensitivity of 0.88 and 0.86, and a specificity of 0.96 and 0.92 during development and validation testing, respectively.

Conclusions In this study, metabolic profiling was used to develop and test a model for determining gestational age during full-term pregnancy progression, and to determine risk of preterm birth. With additional patient validation studies, these algorithms may be used to identify at-risk pregnancies prompting alterations in clinical care, and to gain biological insights into the pathophysiology of preterm birth. Metabolic pathway-based pregnancy modelling is a novel modality for investigation and clinical application development.

INTRODUCTION

Gestational age (GA) dating is a core element of standard prenatal care.1–4 Prenatal ultrasound (US) is an established modality for estimating GA, monitoring fetal growth and screening for fetal anomalies.5 According to the policy statement of the Committee on Obstetric Practice, the American Institute of Ultrasound in Medicine and the Society for Maternal-Fetal Medicine, a pregnancy is considered optimally dated through a combination of last menstrual period (LMP) and an accurate US obtained prior to 22 0/7 weeks.6 Accordingly, LMP is dependent on maternal recall and many pregnancies do not present for a first prenatal US evaluation until the second or third trimester. Thus, there is a need for a molecular method that would complement the potential shortcomings of LMP recall and US dating outside the first trimester. Moreover, it is possible that molecular pregnancy dating will provide greater resolution to pregnancy risk than current information based on calendar dating (LMP) and anthropometrics (US). Although experience is accumulating with the use of second

Strengths and limitations of this study

► The insensitivity of the prediction model to gestational age (GA) window of sample collection increases its flexibility and opportunity for potential clinical use.

► This study is among the first to propose a pathway-based computational methodology to estimate GA and predict preterm birth.

► The overall cohort size is modest, and the distribution of sampling time is different between patients and cohorts.

► It is a retrospective study, a larger prospective cohort study is necessary before applying the estimates and prediction to a broader population for clinical utility.
and third trimester US for an estimation of risk of preterm birth (PTB),7–9 to date these measures have not been widely adopted, are subject to user experience and have reported variable performance characteristics. The availability and expertise of US in disadvantaged areas is limited.10 Therefore, there is a need to develop an alternative measure of fetal progression to estimate GA and pregnancy risk in a variety of settings and especially when US and LMP dates are unavailable or unreliable.

Compared with imaging methodologies, blood-based molecular testing may provide a more reproducible and precise modality in clinical applications for the frequent monitoring of health status and detection of early signs of disease. Genomic, gene expression, protein and metabolite profiles measured in human blood have been increasingly used for the determination of disease risk and to gain disease-specific pathophysiology insight. Attempts at estimating GA using molecular adaptations have included modelling of RNA, protein or immune cell changes, and most recently metabolites in maternal or newborn blood.11–17 Similarly, risk prediction of PTB in clinical settings is currently primarily based on maternal history. Biomarkers have been suggested from genetic and proteomic analyses, but less effort has been focused on understanding maternal metabolic signatures of pregnancy.18–24

In this study, we hypothesised that longitudinal metabolic profiling of pregnancy reflects the temporal progression of fetal development with a high degree of precision. Moreover, we posited that if a normal pregnancy progression profile could be defined in metabolic terms, then aberrations from the normal profile may identify a pregnancy at risk for PTB. Our findings suggest that composite metabolic panel modelling may serve as a reproducible and precision approach to GA dating of pregnancy and prediction of PTB.

MATERIALS AND METHODS

Definition
In this study, a full-term pregnancy was defined as a pregnancy ending with a delivery at ≥37 weeks. PTB was defined by delivery at <35 weeks GA in order to make a complete separation from the full-term subjects.

Study design
The study was conducted in two phases: (1) modelling to devise a metabolite-based estimation of GA during full-term pregnancies and (2) modelling to devise a metabolic panel predictive of PTB (figure 1). In this study, the ‘gold’ standard of GA was US measurement based on the crown-rump length at the first trimester.25 Serum samples were collected in the first, second or third trimester during pregnancy for each individual woman. Each participant had one to four time-points collected prior to delivery. Samples were provided by Stanford Hospital and Clinics (SU) and the University of Alabama (UAB). Metabolic concentrations in each sample were measured by targeted and untargeted mass spectrometry (MS) analysis. Models that estimated GA or predicted PTB were developed using the SU cohort and validated using the UAB cohort. All samples were collected after informed consent was obtained. All statistical analyses were done in R software.

Targeted and global MS analysis
Samples of full-term and preterm patients as well as quality control (QC) samples were injected into the MS. Targeted MS analysis was done through flow injection Liquid Chromatography (UHPLC) system and Quantiva Triple Quadrupole Mass Spectrometer. Global (ie, untargeted) MS analysis was done by using a Vanquish UHPLC system coupled to a Q Exactive plus mass spectrometer and Q Exactive HF hybrid Quadrupole-Orbitrap mass spectrometer.

Data preprocessing and metabolic identification
A data preprocessing procedure was conducted to convert the raw data generated by MS analysis into a matrix of relative concentrations of metabolites versus samples.26 This procedure was done by R package. Metabolic values in each sample were then normalised by the median values measured with QC samples to reduce the batch effects.

Compounds detected by untargeted analyses were matched to metabolites in the Human Metabolome Database by putative identification.27 Accurate mass was used for the mapping. Metabolites were mapped to pathways using Kyoto Encyclopedia of Genes and Genomes and Human Metabolome Database. Only endogenous pathways were considered.

Metabolic compound selection, pathway computation and model development
Metabolites measured by targeted and untargeted MS were aggregated and filtered. The remaining metabolites were mapped to pathways. The value of each pathway...
was calculated as the weighted sum of the normalised concentrations of metabolites on the pathway divided by the number of metabolites. An XGBoost model was developed with the pathway values of samples from full-term patients to estimate the GA. R-squared ($R^2$; goodness-of-fit of the model), root-mean-square error (RMSE) and error distribution were calculated to evaluate the model performance. A second XGBoost model was developed to predict PTB. To evaluate the model performance, Mann-Whitney U tests were used to compare the distribution of final predictive estimates, that is, XGBoost model values, on full-term and PTB samples. Additional details of model development are described in online supplemental appendix text A1. ELISA tests were conducted on the SU and UAB cohorts to evaluate the insulin-like growth factor-binding protein 4 (IGF4)/sex hormone-binding globulin (SHBG) signature, a predictor that was validated in a prospective study as a predictor of spontaneous PTB. Serum concentrations were measured using commercial kits Human IGFBP4 ELISA Kit (Abcam, Burlington, California, USA) and Human SHBG Quantikine ELISA Kit (R&D System). Results were compared with our metabolic model.

Patient and public involvement statement
This retrospective research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

RESULTS

Samples
As shown in figure 2, the SU cohort had 20 full-term pregnancies with 57 blood samples (17, 32 and 8 collected in the first, second and third trimesters, respectively) and 16 preterm pregnancies with 32 blood samples (9, 19 and 4 collected in the first, second and third trimesters, respectively). The UAB cohort had 9 full-term pregnancies with 13 blood samples (8 and 5 in the second and third trimesters, respectively) and 13 preterm pregnancies with 22 blood samples (4 and 18 in the first and second trimesters, respectively). In the SU cohort, two (12.5%) were extremely preterm (<28 weeks) and five (31.3%) were very preterm (28–31 weeks). In the UAB cohort, six (46.2%) were extremely preterm, and three (23.1%) were very preterm. Our SU and UAB cohorts were assembled: no complications of pregnancy were included; all deliveries were singleton and all PTB were spontaneous. Demographics of the two cohorts are shown in table 1.

LC-MS/MS metabolomics
The study targeted 315 metabolites by LC-MS/MS, including 13 categories: acyl-carnitine (11, 3.5%), amino acid (9, 2.9%), fatty acid (6, 1.9%), ceramide (12, 3.8%), ceramide-1-phosphate (8, 2.5%), glycosylceramide (5, 1.6%), phosphatidyl acid (15, 4.8%), phosphatidyethanolamine (52, 16.5%), phosphatidylglycerol (5, 1.6%), phosphatidyl inositol (11, 3.5%), phosphatidylcholine (150, 41.3%), cholesterol ester (16, 5.1%) and sphingomyelin (35, 11.1%). The study also identified 1627 positively and 295 negatively charged compounds through untargeted analyses. Together these formed the initial set of 2237 compounds.

Feature selection of GA estimation modelling
Of the 2237 compounds, 118 had an absolute Pearson’s correlation coefficient of $>0.35$ with GA. The cut-off of $\pm 0.35$ was selected based on the false discovery rate (FDR) values of the mapped pathways (<1% (online supplemental appendix figure A1)). The 118 compounds were mapped to 89 pathways, 33 of which were selected by the XGBoost model. The normalised value of each pathway varied over the course of gestation (online supplemental appendix figure A2). Univariate analysis of the 33 pathways is shown in online supplemental appendix figure A3, and the top 10 pathways in the model is depicted in figure 3. The top 10 pathways included those associated in the metabolisms of: glycerophospholipid, arginine and proline, thiamine, purine, butanoate, galactose, sulfur, phenylalanine and C5-branched dibasic acid.

Performance of GA estimation
The performance of GA estimates on full-term samples was similar in the development phase (SU cohort, $R^2=0.98$, RMSE=1.09) and the validation phase (UAB cohort, $R^2=0.81$, RMSE=2.36) (figure 4). In our validation testing, 66.7% of the estimates were within ±1 week of the US results (online supplemental appendix figure A4). Intriguingly, model performance significantly deteriorated when applied to samples from PTB pregnancies ($R^2=-0.68$ and RMSE=6.06 in validation; see figure 4). It suggested that the relationships between metabolic parameters and full-term pregnancies were not maintained in PTB pregnancies. Furthermore, such disruptions were
notable as early as 10 weeks’ GA (figure 4) or early to mid-gestation. These findings prompted the development of a metabolic-based model of PTB estimation.

**Performance of PTB prediction**

Samples collected before 35 weeks’ GA were used to develop a model that differentiated PTB pregnancies from full-term. As before, the model was developed with the SU cohort that had 20 full-term (54 samples) and 16 preterm (32 samples) pregnancies, and was validated with the UAB cohort that had 9 full-term (13 samples) and 13 preterm (22 samples) pregnancies. In total, 148 metabolic compounds (with Mann-Whitney U test $p<0.05$) were mapped to 66 pathways (FDR <1.5%; see online supplemental appendix figure A5). Further model development selected 10 pathways as strong predictors covering the metabolisms of glycerophospholipid, sphingolipid, taurine and hypotaurine, arachidonic acid, secondary bile acid biosynthesis, glycerolipid, cysteine and methionine, tryptophan and arginine and proline (figure 5).

The level of prediction accuracy was maintained in the validation cohort ($p=5\times10^{-5}$, area under the curve (AUC)=0.92; see figure 6). The prevalence-corrected positive predictive values (PPVs) across model values (ie, scores) were plotted based on the PTB prevalence in Alabama in 2018 (12.5%; see online supplemental appendix figure A6). A threshold value of 0.52 was selected as a high-risk threshold for PTB, which was associated with a PPV of 0.70, a relative risk (RR) of 5.6 compared with the US population baseline (=0.70/12.5%), a sensitivity of 0.86 (19 of 22) and a specificity of 0.92 (12 of 13; figure 7). The sensitivities and specificities with cut-off values are shown in online supplemental table A1.

**Table 1 Maternal characteristics in SU and UAB cohorts**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>SU Full-term (n=20)</th>
<th>SU Preterm (n=16)</th>
<th>UAB Full-term (n=9)</th>
<th>UAB Preterm (n=13)</th>
<th>SU vs UAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>0 (0)</td>
<td>1 (6.3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>20 (100)</td>
<td>5 (31.3)</td>
<td>0 (0)</td>
<td>2 (15.4)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>0 (0)</td>
<td>1 (6.3)</td>
<td>9 (100)</td>
<td>10 (76.9)</td>
<td></td>
</tr>
<tr>
<td>American Indian</td>
<td>0 (0)</td>
<td>2 (12.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Pacific Islander</td>
<td>0 (0)</td>
<td>1 (6.3)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Other/Unknown</td>
<td>0 (0)</td>
<td>6 (37.5)</td>
<td>0 (0)</td>
<td>1 (7.7)</td>
<td></td>
</tr>
<tr>
<td>Hispanic, n (%)</td>
<td>0 (0)</td>
<td>8 (50)</td>
<td>0 (0)</td>
<td>1 (7.7)</td>
<td>0.9 (1)</td>
</tr>
<tr>
<td>Maternal age, year, mean (SD)</td>
<td>31.9 (4.8)</td>
<td>29.8 (7.5)</td>
<td>0.3 (25.6) (5.0)</td>
<td>27.5 (4.5)</td>
<td>0.4 (0.008**</td>
</tr>
<tr>
<td>Gestational age at delivery, weeks, median (IQR)</td>
<td>39.5 (39, 41)</td>
<td>32 (30, 33)</td>
<td>&lt;0.001***</td>
<td>38 (37, 39)</td>
<td>28 (26, 32)</td>
</tr>
<tr>
<td>Having previous pregnancy, n (%)</td>
<td>9 (45)</td>
<td>6 (37.5)</td>
<td>0.7 (9 (100))</td>
<td>13 (100)</td>
<td>0.4 (0.001***</td>
</tr>
<tr>
<td>BMI, kg/m², median (IQR)</td>
<td>22.3 (20.2, 24.7)</td>
<td>27.6 (23.4, 33.9)</td>
<td>0.003***</td>
<td>30.4 (22.3, 33.1)</td>
<td>26.5 (22.6, 36.5)</td>
</tr>
<tr>
<td>History of PTB, n (%)</td>
<td>3 (15)</td>
<td>8 (50)</td>
<td>0.03*</td>
<td>7 (77.8)</td>
<td>13 (100)</td>
</tr>
</tbody>
</table>

*P<0.05; **P<0.01; ***P<0.005.

BMI, body mass index; PTB, preterm birth; SU, Stanford Hospital and Clinics; UAB, University of Alabama.
In the validation cohort, 12 of 13 full-term samples and 19 of 22 preterm samples were classified correctly. The misclassified full-term sample was from a mother that delivered at 37 weeks’ GA. The 19 correctly classified PTB samples were from 13 PTB pregnancies. Of the 13 pregnancies, 9 were identified as high risk at or earlier than 16 weeks’ GA. The median gap between the time of identification and the delivery was 11 weeks’ GA (IQR: 8, 15.5).

To determine the performance of our metabolic model against existing models, a comparison between the metabolite-based model and pathway-based model was performed and is summarised in online supplemental appendix text A2 and online supplemental appendix figure A7.

**DISCUSSION**

**Principal findings**

In this study, we report a panel of metabolic pathways measured in maternal serum that provides an estimation of GA over the course of a full-term pregnancy. A second and distinct set of metabolic pathways was also identified in maternal serum that could distinguish pregnancies ending with PTB (<35 weeks) from full-term (≥37 weeks) with a high degree of precision. The models were developed and validated using two independent cohorts from two different institutions in order to test the robustness of the biological features driving the classifications. Intriguingly, PTB pregnancies do not demonstrate the same temporal relationship as term pregnancies on metabolic modelling across gestation (figure 4). Indeed, PTB pregnancies demonstrate a marked departure from the term metabolic profile (figure 4) that is dramatic (R²=0.98 train and 0.81 test for term model; compared with R²=0.50 train and −0.68 test for PTB pregnancy in term model), and is recognisable as early as 10 weeks’ GA as determined by the current standard of US dating. Recognising the metabolic pathway aberration of PTB pregnancies, a second model was developed using metabolic pathway analyses to quantify the risk of PTB prior to 35 weeks’ GA. Once again, metabolic profiling proved to be robust in identifying PTB pregnancies with a high degree of sensitivity (AUC 0.96 training; AUC 0.92 testing) and
precision (training PPV 0.93 (95% CI 0.78 to 0.99); testing PPV 0.95 (95% CI 0.75 to 1). Taken together, this study demonstrated a powerful new, reproducible methodology for monitoring pregnancy progression and identifying abnormal pregnancies.

Clinical and research implications

The potential clinical utility of developing a test for pregnancy monitoring is appealing. There is a need to develop a more robust method than LMP and an alternative to first trimester US that captures pregnancy progression, a complex relationship of fetal and placental growth, development and function. To support these processes, there is a need for energy transfer between mother and fetus throughout gestation. We therefore reasoned that metabolic phenotyping would be ideally suited to capture this relationship. Despite a modest cohort size, the results of metabolic modelling demonstrate a high degree of concordance with clinical standard US dating performed by experts as reflected by 66.7% of model estimates falling within ±1 week of US results (online supplemental appendix figure A4). Moreover, unlike the deterioration experienced with US dating of pregnancy, metabolic modelling was shown to achieve near equivalent performance in the first, second and third trimesters, indicating the potential for broad clinical applicability that might achieve independence of reliance on accuracy of LMP or concordance among modality testing. The result of PTB prediction is equally robust demonstrating a high degree of precision. Beyond relying on clinical histories or self-reported symptoms, the model proposed here provides a molecular classification that may be more accurate than current methods and further reflect a comprehensive measure of aberrant pregnancy based on metabolic changes. In practice, clinicians could use the PTB prediction model to differentiate high-risk from low-risk patients. Low-risk patients would then be subject to GA estimation panel testing, all from the same blood draw.

A distinct advantage of the PTB risk prediction developed in this study is that it has a wide window of sampling. Samples were collected broadly before 35 weeks’ GA, which is wider than the window of other well-established biomarkers such as fetal fibronectin (between 24 and 34 weeks’ GA),

IBP4/SHBG (19–21 weeks) and inter-alpha-trypsin inhibitor heavy chain 4 protein (24 and 28 weeks).

Relatively stable AUC levels were maintained throughout the diagnostic window (online supplemental text A2). The insensitivity of the prediction model to GA at testing increases its flexibility and opportunity for potential clinical use. An additional advantage of the model herein is the ability for early identification of high-risk women. Although there is no standardised guideline for early gestation management of patients at risk of PTB delivery, metabolic modelling for PTB risk may provide a not previously possible opportunity for early gestation risk mitigation. Clinical trials have suggested that hormone treatment and maternal physical activity modifications applied between 16 and 37 weeks’ GA reduced the PTB rate of women who were deemed at high risk due to a history of prior PTB delivery.28 29 In many cases, PTB cannot be prevented, however any opportunity is deemed highly desirable for even a modest delay (1–2 weeks) in PTB or an enhanced ability to more accurately triage for delivery to centres with the capability to manage profoundly premature neonates.30–32

This study is among the first to propose a pathway-based computational methodology to estimate GA and predict PTB. Metabolic pathways are linked to chemical functions, and the alteration or disruption of specific functions participate in disease phenotypes, facilitating the use of pathways to function as higher-level biomarkers of diseases.33 The role of metabolic pathways in disease diagnosis has been explored in several preliminary clinical studies.34 35 Pathway performance in differentiating patients with disease from healthy controls has been found to be effective compared with using individual metabolites.35 Similarly, we found the pathway-based models had less variability and higher sensitivity than metabolite-based models that were developed using the same population. One plausible explanation for this observation may be attributed to the calculation of pathway values, which represents the sum of individual metabolites and thus may amplify association to outcome relationships. This hypothesis is supported by the FDR comparison (online supplemental appendix figure A8 and A9): pathway-based analysis had lower FDR values than metabolite models. This study adds to the exploration of the feasibility of using pathways for health monitoring and prediction.

In this study, glycerophospholipid metabolism was identified as the most significant contributing pathway for both GA estimation and preterm birth prediction. Glycerophospholipids consist of fatty acid chains and have been previously cited as strong correlates to birth weight, pregnancy duration and risk of preterm birth.36 These same authors also found different polyunsaturated fatty acid components of glycerophospholipid had differential effects on fetal growth. Gao et al has reported a potential association between glycerophospholipid and labour timing in rodent models.37 38 The current study extends those prior observations through a quantitative assessment of the relationship between glycerophospholipid metabolism, GA and the risk of preterm birth. The leading effect of glycerophospholipid pathway metabolism in the current study was positive in both the assessment of GA and risk of preterm birth. These findings add further insight into the role of glycerophospholipid metabolism in human pregnancy. Other contributing pathways for preterm birth prediction such as sphingolipid metabolism, arachidonic acid metabolism and arginine and proline metabolism were also found associated to preterm. Alterations in plasma sphingolipids were found in women who had spontaneous PTB.39 Increase of arachidonic acid metabolism might correlate to bacteria activities that led to preterm labour.40 Plasma level of arginine and citrulline was significantly lowered in preterm babies.41
Taken together, the analysis of the leading pathways found to significantly contribute to the metabolic pregnancy modelling herein provide ample insights to deepen our understanding of pregnancy progression and may facilitate the identification and interpretation of potential therapeutic targets. Furthermore, we speculate that the platform and approaches outlined herein may be extended to the interrogation of additional conditions of pregnancy including abnormalities of placentation, gestational diabetes and fetal growth disturbances among others.

Limitations
This study has several limitations. First, the overall cohort size was modest, and pregnancies with delivery at 35 or 36 weeks were not included in the study. Second, blood samples were collected in a non-uniform manner with respect to GA timing and time of day. The time between two adjacent samples corresponding to the same patient varied. Third, the distribution of samples throughout pregnancy were different between patients and cohorts. In the SU cohort, none of the full-term patients had samples collected between 30 and 37 weeks. In the UAB cohort, none of the full-term patients had sampling in the first trimester, and none of the PTB patients had sampling in the third trimester. Fourth, for methodologic reasons, not all serum analytes could be identified and mapped to known metabolites. Fifth, baseline characteristics of patients were not included in the analysis. Sixth, the study was retrospective, and the participants were solely from California and Alabama. A larger prospective cohort study with a reasonable ratio of full-term to preterm is necessary before applying the estimates and prediction to a broader population for clinical utility.

CONCLUSION
The present study demonstrates that maternal serum-based metabolic profiling is a highly sensitive and accurate method for determining GA and prediction of PTB. The pathway-based analysis supports the hypothesis of the orderly metabolic progression of pregnancy that can be reproducibly captured using metabolic profiling. The robustness of the modelling reinforces the potential appeal for further clinical development and as a platform to investigate the pathophysiology associated with aberrant fetal development and pregnancy progression. This study is the first to report a single blood test for metabolic pathway-based determination of GA dating, and early detection of PTB risk.

Author affiliations
1Department of Health Research and Policy, Stanford University, Stanford, California, USA
2Department of Obstetrics and Gynecology, University of California San Francisco–Fresno, Fresno, California, USA
3Clinical and Translational Research Program, Betty Irene Moore Children’s Heart Center, Lucile Packard Children’s Hospital, Palo Alto, California, USA
4Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA
5Translational Medicine Laboratory, West China Hospital, Chengdu, China
6Department of Cardiopulmonary Medicine, University of California, San Francisco–Fresno, Fresno, California, USA
7Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA

Acknowledgements The authors would like to thank colleagues at the Stanford University Pediatric Proteomics group and the March of Dimes Prematurity Research Center at Stanford University for critical discussions.

Contributors XL, KGS and HJC contributed to concept development and design. JY, RJW and DKS contributed to the acquisition of data. KGS, SH, LZ, XY, LT, LM, SL, RJW, GMS, DKS, JCM and DBM contributed to the analysis and interpretation of data. KGS and SH drafted the manuscript. JY, LZ, LT, XY, LM, SL, RJW, GMS, DKS, JCM, JCM and DBM critically revised the manuscript. All the authors gave final approval of the version to be submitted and agreed to be accountable for all aspects of the work.

Funding This work was supported in part by the March of Dimes Prematurity Research Center at Stanford University, and Stanford Child Health Research Institute. Grant numbers are N/A.

Disclaimer The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the Institutional Review Board of both sites (Protocol #21956).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The datasets used and/or analysed in this study are available on reasonable request to the corresponding author. Once published, data will also be uploaded at the laboratory website (http://translationalmedicine.stanford.edu) and shared with March of Dimes Database.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Xuefeng B Ling http://orcid.org/0000-0002-5386-3884

REFERENCES
24 Hawdon JM, Ward Platt Mp Fa - Aynsley-Green A, Aynsley-Green A. Patterns of metabolic adaptation for preterm and term infants in the first neonatal week. (1468-2044 (Electronic)).
25 Robinson HP. Sonar measurement of fetal crown-rump length as means of assessing maturity in first trimester of pregnancy. (0007- 1447 (print)).
**Fig. A.1.** False discovery rate (FDR) analysis of the metabolic pathways significantly associated with the GA in full-term pregnancies. Pearson $|r|$ was calculated as the correlation between metabolite serological abundance and GA. Only the metabolites with a Pearson $|r|$ higher than the threshold would be selected as part of the significant pathways. FDR was estimated by a permutation-based method (permutation N=1000).
**Fig. A.2.** Profile of the metabolic pathways in the GA estimation model over the course of gestation on SU cohort. All pathways are (A) positively or (B) negatively correlated to the GA (FDR<1%). Profile of each pathway was calculated as the weighted sum of the z-score normalized metabolite serological abundances divided by the number of metabolites. Mean ± standard error of the mean at each time point was plotted.
Fig. A.3. Univariate analysis of the 33 metabolic pathways in the GA estimation model. Pearson correlation coefficient $r$ of each pathway to GA was calculated. *$P<0.05$, **$P<0.01$, ***$P<0.005$. 
### A

<table>
<thead>
<tr>
<th>Trimester and subject number</th>
<th>Δ [model estimation – ultrasound measurements (weeks)] (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt; -2</td>
</tr>
<tr>
<td>SU (T2, n = 19)</td>
<td>0</td>
</tr>
<tr>
<td>SU (T3, n = 8)</td>
<td>12.5</td>
</tr>
<tr>
<td>SU (All, n = 20)</td>
<td>0</td>
</tr>
<tr>
<td>UAB (T2, n = 5)</td>
<td>0</td>
</tr>
<tr>
<td>UAB (T3, n = 5)</td>
<td>20</td>
</tr>
<tr>
<td>UAB (All, n = 9)</td>
<td>11.1</td>
</tr>
<tr>
<td>SU and UAB (T2, n = 24)</td>
<td>0</td>
</tr>
<tr>
<td>SU and UAB (T3, n = 13)</td>
<td>15.4</td>
</tr>
<tr>
<td>SU and UAB (All, n = 29)</td>
<td>3.4</td>
</tr>
</tbody>
</table>

### B

**Fig. A.4.** Comparison of GA estimates using the model and US measurements. (A)

Distributions of differences between GA measured by US and GA estimated by the model, in T2 (weeks 14–27), T3 (weeks 28–40), and T2+T3. n represents the number of full-term patients included. (B) Error distribution of GA estimation on a combination of SU and UAB cohorts in T2, T3, and T2+T3.
**Fig. A.5.** False discovery rate (FDR) analysis of the metabolic pathways significantly associated with PTB. Mann-Whitney U test $P$ measured the difference in metabolite serological abundances between full-term pregnancies and pregnancies ending in PTB. Only metabolites with a Mann-Whitney U test $P$ lower than the threshold were selected as part of the significant pathways. FDR was estimated by a permutation-based method (permutation N=1000).
Population-corrected PPV: 0.70, which is 5.6 times higher than the general population risk in Alabama (12.5%)

Fig. A.6. Stratification of patients by the classification model prediction on the UAB cohort. PPV was corrected by bootstrapping the full-term patients to reach the population PTB prevalence of 12.5% on singleton births in Alabama. Two horizontal dashed lines represent the population mean of PTB risk that is 12.5% (black) and the PPV (= 0.70; red) at the high-risk cutoff. The grey dashed line indicates the high-risk cutoff value (= 0.52). The grey area represents the 95% confidence interval of the PPV. The box plot at the bottom shows the classification model value distribution stratified by the samples. GAB: gestational age at birth. wks: weeks’ GA.
**Fig. A.7.** The performance of the IBP4/SHBG predictor and the metabolic model. The results are stratified by the GA intervals with a BMI at 22–37 kg/m² (A), and by BMI values with a GA interval of 5–20 weeks (B).
Fig. A.8. (A) False discovery rate (FDR) analysis of the metabolites and metabolic pathways significantly associated with the GA in full-term pregnancies. Pearson $|r|$ was calculated as the correlation between metabolite serological abundance and GA. Only the metabolites with a Pearson $|r|$ higher than the threshold (=0.35) would be selected as part of the significant pathways. FDR was estimated by a permutation-based method (permutation N=1000). (B) A comparison of RMSE of the GA estimation model trained by pathways and the model trained by metabolites. All metabolites had a Pearson $|r|>0.35$. RMSE was measured with the full-term samples of the validation (UAB) cohort.
Fig. A.9. (A) False discovery rate (FDR) analysis of the metabolites and metabolic pathways significantly associated with the PTB. Mann-Whitney U test $P$ measured the difference in metabolite serological abundances between full-term pregnancies and pregnancies ending in PTB. Only the metabolites with a Mann-Whitney U test $P$ lower than the threshold ($=0.05$) would be selected as part of the significant pathways. FDR was estimated by a permutation-based method (permutation $N=1000$). (B) A comparison of the AUC of the preterm birth classification model utilizing pathways and the model utilizing metabolites. All the metabolites had a Mann-Whitney U test $P < 0.05$. AUC was measured with the samples of the validation (UAB) cohort.
Table A.1. Sensitivity and specificity of the XGBoost model with respect to the cutoff point.

<table>
<thead>
<tr>
<th>Cutoff</th>
<th>Cohort</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Number of preterm samples identified by the model</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4</td>
<td>SU</td>
<td>0.94</td>
<td>0.78</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>UAB</td>
<td>0.95</td>
<td>0.31</td>
<td>21</td>
</tr>
<tr>
<td>0.5</td>
<td>SU</td>
<td>0.88</td>
<td>0.94</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>UAB</td>
<td>0.86</td>
<td>0.85</td>
<td>19</td>
</tr>
<tr>
<td>0.6</td>
<td>SU</td>
<td>0.81</td>
<td>0.98</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>UAB</td>
<td>0.59</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>0.7</td>
<td>SU</td>
<td>0.53</td>
<td>0.98</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>UAB</td>
<td>0.32</td>
<td>1</td>
<td>7</td>
</tr>
</tbody>
</table>
Text A.1 Metabolic compound selection, pathway computation, and model development

GA estimation

Metabolites measured by targeted and untargeted MS were aggregated and filtered using Pearson correlation coefficient analyses in relation to GA. The remaining metabolites were mapped to pathways. The value of each pathway was calculated as the weighted sum of the normalized concentrations of metabolites on the pathway divided by the number of metabolites. The weight of each metabolite was the absolute value of the Pearson correlation coefficient in relation to GA. Metabolites having positive or negative coefficients were aggregated separately. That is, a pathway could have two values, one for metabolites positively correlated to GA, and the other for those negatively correlated to GA.

A supervised, cross-validated machine-learning technique XGBoost was developed with the pathway values of samples from full-term patients in the SU cohort. An ensemble of regression trees was generated to give a score estimating the GA. The model was validated on the UAB cohort. For a patient that had multiple samples, an ‘integrated’ GA estimate was calculated by shifting the GA estimates of every sample to a reference point for obtaining the median. Error distribution of GA estimation based on patients was calculated as the distribution of the differences between the ‘integrated’ GA estimates and the US measurement.

PTB prediction
Samples collected before 35 weeks’ GA were selected to build the model to predict PTB. Mann–Whitney U test was used to select the initial candidate metabolites that were then mapped to pathways. The value of each pathway was calculated as the weighted sum of the normalized concentrations of metabolites on the pathway divided by the number of metabolites. The weight of each metabolite was the absolute value of the ratio of median of full-term samples to PTB samples. Like the GA estimation, pathways could have two values that depended on the ratio of median greater or less than 1. An XGBoost model was developed utilizing samples from the SU cohort and validated with the UAB cohort.
**Text A.2 Metabolite model vs. IBP4/SHBG in predicting PTB**

We conducted ELISA tests on the SU and UAB cohorts to evaluate the IBP4/SHBG signature, a predictor that was validated in a prospective study as a predictor of spontaneous PTB. Commercial kits Human IGFBP4 ELISA Kit (Abcam, Burlingame, CA, USA) and Human SHBG Quantikine ELISA Kit (R&D System Inc.) were used. AUC of the predictor was calculated in different GA intervals and with different maternal BMI values, and was compared to the performance of the metabolic model.

With a BMI of >22 and ≤37 kg/m², the AUC values of the IBP4/SHBG predictor peaked at 15–20 weeks’ GA (SU: 0.833; UAB: 1), and dropped rapidly after 20 weeks (Figure A below). The AUC values were lower with extreme BMI (0.7 at BMI ≤20 kg/m² and 0.63 at BMI >27 kg/m²; see Figure B below). These findings are consistent with the previous validation study. Compared with the IBP4/SHBG predictor, the metabolic model has a more stable AUC performance over the gestation and different BMI values in SU ($P = 0.03$). In UAB at >18 weeks’ GA, the AUC of IBP4/SHBG dropped from 0.6 to 0.3, while the AUC of the metabolic model was above 0.8.